No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo

References

• Henke M, Laszig R, Rübe C, Schäfer U, Haase K-D, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255–60
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005; 23: 5960–72
   PubMed Web of Science ®Google Scholar
• Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67: 39–61
   PubMed Web of Science ®Google Scholar
• Melosky BL. Erythropoiesis-stimulating agents: Benefits and risks in supportive care of cancer. Curr Oncol 2008; 15: S10–S15
   Google Scholar
• Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006; 12: 332–9
   PubMed Web of Science ®Google Scholar
• Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: Implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007; 110: 477–88
   PubMed Web of Science ®Google Scholar
• Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G, et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005; 7: 537–43
   PubMed Web of Science ®Google Scholar
• Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005; 24: 4442–9
   PubMed Web of Science ®Google Scholar
• LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Ze, Hall C, et al. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 2006; 5: 347–55
   Google Scholar
• Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107: 1892–5
   PubMed Web of Science ®Google Scholar
• Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 2006; 24: 4708–13
   PubMed Web of Science ®Google Scholar
• Agarwal N, Gordeuk VR, Prchal JT. Are erythropoietin receptors expressed in tumors? Facts and fiction–more careful studies are needed. J Clin Oncol 2007; 25: 1813–4
   PubMedGoogle Scholar
• Della Ragione F, Cucciolla V, Borriello A, Oliva A, Perrotta S. Erythropoietin receptors on cancer cells: A still open question. J Clin Oncol 2007; 25: 1812–3
   Google Scholar
• Jelkmann W, Laugsch M. Problems in identifying functional erythropoietin receptors in cancer tissue. J Clin Oncol 2007; 25: 1627–8
   PubMed Web of Science ®Google Scholar
• Sizer KC. Heat shock protein 70, erythropoietin, and cancer. J Clin Oncol 2007; 25: 4326
   PubMedGoogle Scholar
• Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999; 253: 143–56
   PubMed Web of Science ®Google Scholar
• Ammarguellat F, Llovera M, Kelly PA, Goffin V. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 2001; 284: 1031–8
   PubMed Web of Science ®Google Scholar
• Kjellén E, Sasaki Y, Kjellström J, Zackrisson B, Wennerberg J. Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical trauma. Acta Otolaryngol 2006; 126: 545–7
   PubMed Web of Science ®Google Scholar
• Henriksson E, Baldetorp B, Borg A, Kjellen E, Akervall J, Wennerberg J, et al. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol 2006; 45: 300–5
   PubMed Web of Science ®Google Scholar
• Verdier F, Gomez S, Lacombe C, Mayeux P. Selected anti-Epo receptor antibodies predict Epo receptor expression. Blood 2006; 108: 1106
   PubMedGoogle Scholar
• Jones SS, D'Andrea AD, Haines LL, Wong GG. Human erythropoietin receptor: Cloning, expression, and biologic characterization. Blood 1990; 76: 31–5
   PubMed Web of Science ®Google Scholar
• Wognum AW, Lansdorp PM, Humphries RK, Krystal G. Detection and isolation of the erythropoietin receptor using biotinylated erythropoietin. Blood 1990; 76: 697–705
   PubMed Web of Science ®Google Scholar
• Verdier F, Walrafen P, Hubert N, Chrétien S, Gisselbrecht S, Lacombe C, et al. Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem 2000; 275: 18375–81
   PubMed Web of Science ®Google Scholar
• Buemi M, Galeano M, Sturiale A, Ientile R, Crisafulli C, Parisi A, et al. Recombinant human erythropoietin stimulates angiogenesis and healing of ischemic skin wounds. Shock 2004; 22: 169–73
   PubMedGoogle Scholar
• Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 2003; 163: 993–1000
   PubMed Web of Science ®Google Scholar